Description
| Product Name: | VivoGenie Anti-Human IL-17A (Ixekizumab) Biosimilar Antibody - Low Endotoxin |
| SKU: | IVMB0417 |
| Size: | 1mg, 5mg, 25mg, 50mg, 100mg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | LY2439821 |
| Target: | IL-17A |
| Isotype: | Human IgG4κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | ELISA, FA, FC, IF, WB |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Active |
| Synonyms: | CTLA8, Interleukin 17A |
| Product Concentration: | ≥ 5.0 mg/ml |
| Purity: | ≥95% by SDS Page, ≥95% Monomer by analytical SEC |
| Immunogen: | Humanized Antibody from Mouse clone 2321 |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| Antigen Distribution: | IL-17A is expressed by Th17 cells, mast cells, and neutrophils. |
| Formulation: | This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ixekizumab. This product is for research use only. Ixekizumab has similar binding affinity to and neutralization of human andcynomolgus monkey IL-17A as well as weak binding to rabbit IL-17A. No binding is detected against rat or mouse IL-17A. |
IL-17 is a group of proinflammatory cytokines (IL-17A to IL-17F) released by T helper 17 (Th17) cells1. IL-17A is the key effector cytokine of the group 1 and is involved in normal inflammatory and immune responses. Additionally, increased IL-17A plays an important role in the pathogenesis of ankylosing spondylitis (AS), a chronic autoimmune inflammatory disease that primarily affects the axial skeleton, and in the progression of psoriatic arthritis1 and plaque psoriasis. Ixekizumab was developed as an IL-17A inhibitor for the treatment of AS, psoriasis, and psoriatic arthritis and has been approved for the treatment of some patients with plaque psoriasis, psoriatic arthritis, AS, and non-radiographic axial spondyloarthritis. Ixekizumab is a fully humanized monoclonal antibody that binds selectively to IL-17A and inhibits its interaction with the IL-17 receptor, thereby inhibiting the release of proinflammatory cytokines and chemokines. Ixekizumab disrupts the proinflammatory cascade present in psoriasis, resulting in decreased expression of cytokines from multiple T cell subsets as well as decreased keratinocyte proliferation and differentiation.
| Ligand/Receptor: | Il-17R |
| State of Matter: | Liquid |
| Regulatory Status: | Research Use Only |
| Product Preparation: | Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Storage and Handling: | Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. |
| UniProt: | Q16552 |
| Research Area: | Autoimmune, Biosimilars, Cancer, Immunology, Inflammatory Disease |
